More than 10% of adults in the US use GLP-1 drugs. A parallel phenomenon is emerging: microdosing for wellness and longevity purposes, seeking metabolic benefits with fewer side effects and lower cost. Without rigorous scientific evidence to support it, this practice is marketed in anti-aging clinics. From the visual epidemiology perspective, it is crucial to map this trend to understand its real scale and potential risks.
3D Modeling of Spread and Evidence Gap 📊
3D data visualization allows mapping the geographic and demographic prevalence of this off-label use, overlaying prescription data, online sales, and clinic activity. Predictive models of its spread can be created based on social media patterns and direct marketing. Interactive infographics should contrast the reported anecdotal benefits, such as inflammation reduction, with the vast gap in high-quality scientific data on long-term efficacy and safety in healthy populations.
Simulation Does Not Replace Scientific Study ⚠️
Although we can simulate impact scenarios on population metabolic health, these projections are hypothetical. The true critical visualization is the one that shows the disparity between rapid commercialization and the slowness of rigorous research. Visual epidemiology must serve to illuminate this gap, promoting surveillance and serious study of a phenomenon that is already in the population.
How can we use data visualization tools to map and analyze the emerging trend of GLP-1 microdosing for wellness purposes, despite the scarcity of official clinical data?
(PS: modeling health data is like dieting: you start with energy and end up quitting)